Department of Biomedical Engineering, Duke University, Durham, NC, USA.
Int J Hyperthermia. 2013 Sep;29(6):501-10. doi: 10.3109/02656736.2013.819999. Epub 2013 Aug 7.
A diverse range of drug delivery vehicles have been developed to specifically target chemotherapeutics to solid tumours while avoiding systemic dose-limiting toxicity. Many of these active targeting strategies display limited efficacy because they rely on subtle differences in expression patterns between pathogenic tissue and healthy tissue. In contrast, drug delivery systems that exploit thermoresponsive behaviour allow a clinician to spatially and temporally control the accumulation and/or release of the toxic agents within tumour tissue by simply applying mild hyperthermia (defined as 39-43 °C) to the desired site. Although thermally sensitive materials comprise a significant portion of the literature on novel drug delivery systems, only a few systems have been methodically tuned to respond within this narrowly defined physiological temperature range in an in vivo environment. This review discusses the materials and strategies developed to control the primary tumour through the combined application of hyperthermia and chemotherapy.
已经开发出了多种药物输送载体，专门将化疗药物靶向递送至实体瘤，同时避免全身剂量限制毒性。这些主动靶向策略中的许多策略显示出有限的疗效，因为它们依赖于致病组织和健康组织之间表达模式的细微差异。相比之下，利用温度响应行为的药物输送系统允许临床医生通过简单地将温和的热疗（定义为 39-43°C）施加到所需部位，在空间和时间上控制肿瘤组织内毒性剂的积累和/或释放。尽管热敏材料构成了新型药物输送系统文献的重要部分，但只有少数系统经过系统调整，以在体内环境中这一狭窄的生理温度范围内进行响应。本文综述了通过热疗和化疗的联合应用来控制原发性肿瘤的材料和策略。
